Identification
- Generic Name
- Safflower oil
- DrugBank Accession Number
- DB09446
- Background
Safflower (Carthamus tinctorius L) is a herbaceous plant in the Asteraceae family. Extracted from the seeds of safflowers, safflower oil is a rich source of various saturated fatty acids, monounsaturated fatty acid (oleic acid) or essential n-6 polyunsaturated fatty acid (PUFA) linoleic acid 1,3, depending on the flower type. Safflower oil with a higher content of polyunsaturated fatty acids is more commonly used as an edible oil. The constituents of safflower oil also include alpha-tocopherol, gamma-tocopherol, and mixed Tocopherol 4. Safflower oil is approved for use as an indirect additive in food contact substances and is readily available as a food ingredient. Gamma linolenic acid (GLA) safflower oil is marketed as an over-the-counter dietary supplement.
- Type
- Biotech
- Groups
- Approved, Investigational
- Synonyms
- Carthamus tinctorius seed oil
- Safflower oil
Pharmacology
- Indication
No approved therapeutic indications.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Safflower oil contains n-6 polyunsaturated fatty acids (PUFAs) such as conjugated linoleic acid (CLA) which may have lipid-lowering and anti-inflammatory actions, as well as tocopherols. In a study of post-menopausal, obese women with type 2 diabetes, safflower oil supplementation was associated with improved metabolic endpoints including HbA1c, fasting glucose, insulin sensitivity estimated by QUICKI, HDL cholesterol, CRP, and adiponectin 1.
- Mechanism of action
Linoleic acid in safflower oil may decrease serum cholesterol levels by activating hepatic uptake and biliary excretion of serum cholesterol 2. Tocopherol in safflower oil is a radical scavenger with antioxidant properties.
- Absorption
Fatty acids and tocopherol from safflower oil are expected to undergo absorption within the digestive tract.
- Volume of distribution
No pharmacokinetic data available.
- Protein binding
No pharmacokinetic data available.
- Metabolism
No pharmacokinetic data available.
- Route of elimination
No pharmacokinetic data available.
- Half-life
No pharmacokinetic data available.
- Clearance
No pharmacokinetic data available.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The LD50 in rats is >5.0 g/kg following oral administration and >50 g/kg following intraperitoneal administration 5.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Carthaphy Cap Safflower oil (912 mg / cap) + Pyridoxine hydrochloride (.5 mg / cap) Capsule Oral Phyto Health Corporation 1973-12-31 2003-11-27 Canada 
Liposyn II Safflower oil (10 g/100mL) + Egg phospholipids (1.2 g/100mL) + Soybean oil (10 g/100mL) Injection, emulsion Intravenous Hospira, Inc. 1984-08-27 2011-02-01 US 
Liposyn II Safflower oil (5 g/100mL) + Egg phospholipids (1.2 g/100mL) + Soybean oil (5 g/100mL) Injection, emulsion Intravenous Hospira, Inc. 1984-08-27 2011-02-01 US Liposyn II 10% Safflower oil (5 %) + Egg phospholipids (0.9 %) + Soybean oil (5 %) Emulsion Intravenous Hospira Healthcare Ulc 1987-12-31 2014-08-01 Canada Liposyn II 20% Safflower oil (10 %) + Egg phospholipids (1.2 %) + Soybean oil (10 %) Emulsion Intravenous Hospira Healthcare Ulc 1987-12-31 2014-08-01 Canada
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 65UEH262IS
- CAS number
- 8001-23-8
References
- General References
- Asp ML, Collene AL, Norris LE, Cole RM, Stout MB, Tang SY, Hsu JC, Belury MA: Time-dependent effects of safflower oil to improve glycemia, inflammation and blood lipids in obese, post-menopausal women with type 2 diabetes: a randomized, double-masked, crossover study. Clin Nutr. 2011 Aug;30(4):443-9. doi: 10.1016/j.clnu.2011.01.001. Epub 2011 Feb 3. [Article]
- Sato M, Yoshida S, Nagao K, Imaizumi K: Superiority of dietary safflower oil over olive oil in lowering serum cholesterol and increasing hepatic mRnas for the LDL receptor and cholesterol 7alpha-hydroxylase in exogenously hypercholesterolemic (exHC) rats. Biosci Biotechnol Biochem. 2000 Jun;64(6):1111-7. doi: 10.1271/bbb.64.1111. [Article]
- Cox C, Mann J, Sutherland W, Chisholm A, Skeaff M: Effects of coconut oil, butter, and safflower oil on lipids and lipoproteins in persons with moderately elevated cholesterol levels. J Lipid Res. 1995 Aug;36(8):1787-95. [Article]
- Masterjohn C: The anti-inflammatory properties of safflower oil and coconut oil may be mediated by their respective concentrations of vitamin E. J Am Coll Cardiol. 2007 May 1;49(17):1825-6. doi: 10.1016/j.jacc.2007.04.001. Epub 2007 Apr 16. [Article]
- SAFFLOWER OIL - National Library of Medicine HSDB Database - Toxnet - NIH [Link]
- External Links
- MSDS
- Download (47.2 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Neuropathic Pain 1 4 Completed Treatment Osteoarthritis (OA) 1 4 Completed Treatment Trigeminal Neuralgia (TN) 1 4 Recruiting Treatment Mechanical Low Back Pain 1 3 Completed Treatment Chronic Pain / Neuropathic Pain / Pain / Postoperative pain 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral Injection, emulsion Intravenous Emulsion Intravenous Patch Cutaneous Paste Cutaneous Capsule, gelatin coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
Property Value Source boiling point (°C) 338-366 National Library of Medicine HSDB Database water solubility Insoluble National Library of Medicine HSDB Database
Drug created at November 30, 2015 19:10 / Updated at May 21, 2021 10:21